Li and colleagues (3) report the synthesis and properties of a cephalosporin that releases the antimicrobial agent triclosan when the ␤-lactam bond is enzymatically hydrolyzed and describe this concept as a "novel prodrug strategy to overcome drug resistance." This claim of novelty must not be allowed to go unchallenged. As long ago as 1976, scientists from Glaxo in the United Kingdom (4) described a precisely analogous compound, the cephalosporin MCO, that ejected the antimicrobial compound pyrithione ("Omadine") when an organism producing ␤-lactamase was encountered. Since then, there have been several other compounds synthesized with this antimicrobial strategy in mind, based on cephalosporins, carbapenems, and penems, as detailed in reviews (1, 2) . A more recent development has been to harness this property of the cephalosporin nucleus as a potential targeting mechanism for anticancer drugs (5). 
